C2T2's Executive Director, Martin Fuss, M.D., Ph.D.
ViewRay's C2T2 comprises clinicians from leading institutions around the world who are focused on evidence gathering to support MR-guided radiation therapy. This group includes:
At the inaugural meeting of the C2T2 on September 23, 2017, participants formalized the group's first key initiative – a multi-center, prospective, single-arm clinical trial focused on locally advanced unresectable pancreatic cancer. Pancreatic cancer presents considerable radiation targeting challenges given the known limitations of conventional CT image guidance. The novel abilities provided by live MR guidance combined with daily online treatment adaptation have potentially enabled a new approach in pancreatic cancer therapy. Through this trial the group looks to explore new opportunities to improve survival and quality of life for this deadly disease.
To be informed of additional information about the Pancreatic Cancer Trial please sign up for our pancreatic trial updates here.
For the complete press release about the pancreatic cancer trial click to read the pancreatic cancer trial press release.